Ivermectin 3 mg tablets represent the lowest standard oral strength of ivermectin used in systemic antiparasitic therapy. This dosage form is widely prescribed for scabies, strongyloidiasis, and resistant lice infestations, providing flexible weight‑based dosing across clinical scenarios. Ivermectin 3 mg is available both as a generic formulation and as part of the branded Stromectol line, offering identical active ingredient performance with differences in manufacturing standards and brand‑level quality control.
Compared with the higher 6 mg strength, ivermectin 3 mg tablets allow more precise dose adjustments, especially in patients requiring fine‑tuned weight‑based regimens. This page provides a complete overview of the 3 mg dosage form, including pharmacology, clinical indications, safety, and comparison with other strengths. Explore related sections: Ivermectin oral, Stromectol, Ivermectin 6 mg.
Ivermectin 3 mg is the lowest standard oral tablet strength used in systemic antiparasitic therapy. It contains the same active ingredient as all oral ivermectin formulations and is available in both generic ivermectin and the branded version Stromectol 3 mg. The 3 mg strength is historically the reference dosage form cited in clinical guidelines, product monographs, and weight‑based dosing schemes for systemic parasitic infections.
The definition of the 3 mg dosage is structural rather than therapeutic: it represents a standardized unit used to build total systemic doses by combining multiple tablets. This description is informational and does not constitute dosing advice. The 3 mg strength allows fine‑grained construction of weight‑based regimens, especially in lower‑weight categories or protocols requiring precise tablet counts.
Compared with the 6 mg tablet, ivermectin 3 mg offers greater flexibility but requires more tablets to reach higher total doses. The 6 mg strength simplifies tablet counts but does not change the drug’s mechanism of action, bioavailability, or systemic effect. Both strengths are fully interchangeable and differ only in tablet size and excipient composition.
Ivermectin 3 mg is produced by multiple manufacturers as a generic formulation, while Stromectol 3 mg represents the originator brand. The differences between them are commercial — branding, excipients, and price — not pharmacological. Therapeutic efficacy, mechanism of action, and systemic distribution remain identical across all versions.
| Parameter | Value |
|---|---|
| Strength | 3 mg oral tablet |
| Role in dosing | Used to construct informational weight‑based regimens |
| Difference vs 6 mg | Same effect; 6 mg reduces tablet count |
| Generic vs brand | Identical efficacy; differs in branding and price |
| Associated products | Generic ivermectin, Stromectol 3 mg |
Ivermectin 3 mg is supplied as a solid oral tablet designed for systemic antiparasitic use. The tablet is typically small, film‑coated, and optimized for stable dissolution in the gastrointestinal tract. Although manufacturers may vary, the core dosage form remains consistent across both generic ivermectin and Stromectol 3 mg, ensuring identical delivery of the active ingredient.
The formulation includes standard excipients such as microcrystalline cellulose, starch derivatives, magnesium stearate, and film‑coating agents. These inactive components support tablet stability, uniformity, and absorption but do not alter the pharmacologic effect of ivermectin. Differences in excipients between brands are commercial rather than therapeutic.
Ivermectin 3 mg tablets are commonly packaged in blister strips or boxed units, protecting the tablets from moisture and ensuring long‑term stability. Packaging formats may differ by region, but the dosage strength and tablet characteristics remain standardized.
The 3 mg strength is produced by multiple generic manufacturers, while Stromectol 3 mg represents the originator brand. Both versions contain the same active ingredient and deliver equivalent systemic activity, differing only in branding, excipients, and price.
| Parameter | Value |
|---|---|
| Dosage form | Oral tablet, film‑coated |
| Excipients | Cellulose, starch derivatives, magnesium stearate, coating agents |
| Packaging | Blister packs or boxed units |
| Manufacturers | Multiple generics; originator brand Stromectol |
Ivermectin 3 mg tablets act through a highly selective neurophysiological mechanism targeting glutamate‑gated chloride channels in invertebrate nerve and muscle cells. By binding to these channels, ivermectin increases chloride ion influx, leading to cellular hyperpolarization. Humans do not possess glutamate‑gated chloride channels, which explains the drug’s strong safety margin and selective antiparasitic activity. More mechanistic detail is available at Ivermectin MOA.
The resulting hyperpolarization produces paralysis of parasites, preventing them from feeding, attaching, or reproducing. In nematodes and ectoparasites, this paralysis is irreversible and ultimately leads to death. The 3 mg strength does not alter the mechanism of action; it is simply a dosage unit used to construct systemic regimens.
As an oral systemic formulation, ivermectin distributes through the bloodstream and peripheral tissues, reaching parasites located beyond the skin surface. This systemic reach is essential for infections such as strongyloidiasis, crusted scabies, and resistant lice, where parasites inhabit deeper tissues or circulate throughout the body. The MOA of the 3 mg tablet is identical to that of 6 mg tablets, generic ivermectin, and Stromectol.
The pharmacokinetic profile of Ivermectin 3 mg is identical to that of all oral ivermectin formulations, including the 6 mg strength and branded Stromectol. The 3 mg tablet represents a dosage unit rather than a unique formulation, and its systemic behavior reflects ivermectin’s intrinsic lipophilicity, hepatic metabolism, and transporter‑mediated distribution. A broader overview is available at Ivermectin PK.
Absorption. After oral administration, ivermectin is absorbed in the gastrointestinal tract. Its lipophilic nature supports efficient uptake, though absolute bioavailability varies between individuals. Effect of high‑fat meals. Co‑administration with fatty food significantly increases systemic exposure by enhancing dissolution and absorption. This effect is consistent across all tablet strengths, including 3 mg.
Distribution. Ivermectin is highly lipophilic and strongly protein‑bound, enabling extensive distribution into peripheral tissues. This systemic reach is essential for infections involving circulating larvae or deep‑tissue parasite reservoirs.
Metabolism. The drug undergoes hepatic biotransformation primarily via CYP3A4, with minor contributions from other oxidative pathways. Because the 3 mg tablet contains the same active ingredient and excipients as other strengths, its metabolic profile is unchanged.
Elimination. Excretion occurs mainly through the biliary–fecal route, with minimal renal clearance. The elimination half‑life is prolonged due to strong tissue binding, supporting interval‑based systemic regimens used in antiparasitic therapy.
| Parameter | Value |
|---|---|
| Absorption | Enhanced with high‑fat meals; variable baseline bioavailability |
| Distribution | Highly lipophilic; extensive tissue penetration; strong protein binding |
| Metabolism | Primarily via CYP3A4; oxidative hepatic pathways |
| Elimination | Biliary–fecal excretion; long elimination half‑life |
Ivermectin 3 mg is the foundational oral tablet strength used in systemic antiparasitic therapy. Its indications fully overlap with those of all oral ivermectin formulations, including generic versions and branded Stromectol. The 3 mg strength is not a different drug — it is a dosage unit used to construct weight‑based systemic regimens. Below are the primary parasitic infections where ivermectin is widely used. Expanded clinical overviews are available on Ivermectin for scabies, Ivermectin for strongyloides, and Ivermectin for lice.
Scabies. Ivermectin 3 mg is used in systemic therapy for classic, crusted, and treatment‑resistant scabies. Its systemic distribution allows it to reach mites and larvae located beyond the epidermis, making it especially useful when topical therapy is insufficient.
Strongyloidiasis. Ivermectin is the reference standard for Strongyloides stercoralis, a systemic nematode infection requiring deep‑tissue penetration. The 3 mg strength is commonly used to construct informational weight‑based regimens for this indication.
Lice. Oral ivermectin is used for resistant or recurrent lice infestations, particularly when topical agents fail or are impractical. Systemic exposure ensures coverage even when parasites are difficult to reach.
Although ivermectin 3 mg and 6 mg tablets are therapeutically identical, the 3 mg strength plays a unique structural role in regimen construction.
Flexible dose construction. The 3 mg tablet allows fine‑grained assembly of informational weight‑based regimens. This flexibility is useful in lower‑weight categories or protocols requiring precise tablet counts.
Informational weight‑based calculations. In clinical guidelines, total systemic doses are often expressed in mg/kg. The 3 mg unit makes it easier to match these informational calculations without altering pharmacodynamics.
Clinical scenarios favoring 3 mg. The 3 mg strength is convenient when: tablet precision is needed, patient weight falls between standard ranges, or protocols require multi‑tablet combinations. The 6 mg tablet simplifies tablet count but reduces flexibility.
| Parameter | 3 mg | 6 mg |
|---|---|---|
| Use in scabies | Flexible tablet combinations; precise regimen construction | Fewer tablets; same therapeutic effect |
| Use in strongyloidiasis | Fine‑tuned mg/kg calculations | Simplified tablet count for higher totals |
| Use in lice | Convenient for lower‑weight categories | Convenient for higher‑weight categories |
| Flexibility | Maximum precision | Maximum convenience |
The following section provides an informational overview of how ivermectin 3 mg tablets are structured within systemic antiparasitic regimens. These patterns reflect how treatment protocols are typically described in clinical literature and guidelines, without offering individualized dosing instructions. Because the 3 mg tablet is a modular dosage unit, it is frequently used to construct weight‑based systemic regimens for a wide range of parasitic infections.
In clinical references, ivermectin is commonly described as being administered in single‑dose or two‑dose interval‑based patterns. These informational schemes are designed to target parasites at different stages of their life cycle. The 3 mg strength is used to assemble the total systemic amount by combining multiple tablets, depending on the weight‑based calculations described in guidelines. These patterns apply equally to generic ivermectin and Stromectol 3 mg.
Informational protocols often include repeat courses when dealing with persistent infestations, high environmental exposure, or infections known for autoinfection cycles. Repeat intervals are typically structured to account for parasite maturation timelines. The 3 mg tablet allows precise construction of these repeated systemic doses, especially in scenarios where exact tablet counts are required.
In infections associated with high parasite load, informational sources describe the potential for stronger inflammatory responses due to rapid parasite death. In such contexts, some protocols outline staged or interval‑based systemic patterns to moderate the intensity of parasite clearance. These considerations are mechanistic and apply equally to all ivermectin strengths, but the 3 mg tablet offers greater flexibility for constructing finely adjusted informational regimens.
| Pattern | Description |
|---|---|
| Single‑dose schemes | Used in many antiparasitic protocols; total dose built from 3 mg units |
| Two‑dose interval schemes | Second informational dose after a defined interval for life‑cycle coverage |
| Repeat courses | Structured repeats for persistent or high‑exposure infections |
| High‑burden protocols | Staged or interval‑based informational patterns for heavy parasite loads |
The safety profile of Ivermectin 3 mg is identical to that of all oral ivermectin formulations, including the 6 mg strength and branded Stromectol. Contraindications and precautionary considerations relate to the pharmacology of ivermectin itself rather than the tablet strength. A broader overview is available at Ivermectin oral — precautions.
Ivermectin 3 mg is generally avoided in individuals with known hypersensitivity to ivermectin or other macrocyclic lactones. Because ivermectin undergoes hepatic metabolism, significant liver impairment may alter systemic clearance and increase exposure. Conditions associated with compromised blood–brain barrier integrity may increase the risk of central nervous system penetration, making them a relative contraindication in certain contexts. These considerations apply equally to generic ivermectin and Stromectol.
Certain groups require additional caution due to altered pharmacokinetics or increased susceptibility to adverse reactions. These include frail older adults, individuals with severe systemic illness, and those with hepatic dysfunction. In endemic regions, people with high Loa loa microfilarial loads may experience Mazzotti‑type inflammatory reactions due to rapid parasite death. Pregnancy and breastfeeding require careful evaluation because systemic exposure may affect fetal or neonatal development.
Ivermectin is metabolized primarily by CYP3A4 and transported by P‑glycoprotein (P‑gp). Strong CYP3A4 inhibitors (e.g., azoles, macrolides, antiretrovirals) may increase systemic exposure, while inducers may reduce it. P‑gp inhibitors can increase tissue penetration, including potential CNS exposure. These interactions are mechanistic and apply equally to the 3 mg and 6 mg strengths.
| Category | Description |
|---|---|
| General contraindications | Hypersensitivity, severe hepatic impairment, compromised BBB |
| Special populations | Pregnancy, breastfeeding, frail adults, high Loa loa burden |
| Drug interactions | CYP3A4 inhibitors/inducers; P‑gp modulators |
The interaction profile of Ivermectin 3 mg is identical to that of all oral ivermectin formulations, including the 6 mg strength and branded Stromectol. Interactions depend on the pharmacology of ivermectin itself rather than tablet size. Key mechanisms involve CYP3A4 metabolism, P‑glycoprotein (P‑gp) transport, and additive effects with other antiparasitic agents. A broader overview is available on Ivermectin oral interactions.
Ivermectin is metabolized primarily by CYP3A4, making it sensitive to co‑administered inhibitors and inducers. • CYP3A4 inhibitors (azole antifungals, macrolides, antiretrovirals) may increase systemic exposure. • CYP3A4 inducers may reduce exposure, potentially lowering antiparasitic activity. These effects apply equally to 3 mg and 6 mg tablets.
Ivermectin is a substrate of P‑gp, an efflux transporter that limits penetration into sensitive tissues, including the CNS. P‑gp inhibitors (certain calcium channel blockers, macrolides, immunosuppressants) may increase tissue distribution and raise the risk of neurological exposure. Combined CYP3A4 and P‑gp inhibition can amplify systemic levels.
Ivermectin does not have a direct pharmacokinetic interaction with alcohol, but concurrent use may intensify overlapping effects such as dizziness, fatigue, or gastrointestinal discomfort. Alcohol may also indirectly influence hepatic metabolism, which is relevant given ivermectin’s CYP3A4 dependence.
Ivermectin is sometimes used alongside albendazole or mebendazole in informational combination protocols. These combinations may increase the likelihood of additive gastrointestinal or systemic reactions. Such interactions are pharmacodynamic rather than metabolic and apply equally to all ivermectin strengths.
| Interaction Type | Description |
|---|---|
| CYP3A4 inhibitors | Increase systemic exposure; may intensify pharmacologic effects |
| P‑gp modulators | Alter tissue distribution; may increase CNS penetration |
| Anthelmintics | Potential additive effects in combination protocols |
| Alcohol | May enhance overlapping side effects; informational caution |
The adverse‑effect profile of Ivermectin 3 mg is identical to that of all oral ivermectin formulations, including the 6 mg strength and branded Stromectol. Most reactions are mild and transient, reflecting both the pharmacologic action of ivermectin and the body’s response to parasite elimination. A broader overview is available on Ivermectin general safety.
Frequently reported reactions include dizziness, headache, fatigue, nausea, abdominal discomfort, and diarrhea. Mild skin symptoms such as itching or rash may also occur. These effects are usually short‑lived and often represent the immune system’s response to dying parasites rather than direct drug toxicity. The 3 mg strength does not alter the frequency or severity of these reactions.
Less common adverse events include hypotension, tachycardia, confusion, ataxia, or other neurological symptoms. These reactions are more likely in individuals with impaired blood–brain barrier function or significant hepatic dysfunction, which may increase systemic exposure. Such events are rare and apply equally to generic ivermectin and Stromectol.
In infections with high parasite burden, patients may experience Mazzotti‑type reactions caused by the immune response to rapid parasite death. These may include fever, lymph node swelling, joint pain, intense itching, or inflammatory skin changes. These reactions are mechanistic and not related to the 3 mg strength specifically; they occur with all oral ivermectin formulations.
| Category | Description |
|---|---|
| Common effects | Dizziness, headache, nausea, abdominal discomfort, mild rash |
| Rare effects | Hypotension, tachycardia, neurological symptoms in susceptible individuals |
| Mazzotti‑type reactions | Fever, lymphadenopathy, pruritus, inflammatory response to parasite death |
Ivermectin 3 mg and Ivermectin 6 mg contain the same active ingredient and provide identical systemic antiparasitic activity. The difference lies not in pharmacology but in tablet strength, which influences dosing flexibility, convenience, pricing, and market availability. A broader overview of the higher‑strength formulation is available on Ivermectin 6 mg.
The 3 mg tablet offers maximum precision for constructing informational weight‑based regimens. It is especially useful when exact tablet counts are needed, when patient weight falls between standard ranges, or when protocols require finely tuned mg/kg calculations. The 6 mg tablet simplifies dosing by reducing the number of tablets required for higher systemic totals, improving convenience without altering therapeutic effect.
In informational clinical frameworks, 3 mg is often referenced in guidelines because it is the historical standard strength. It is convenient in lower‑weight categories and in regimens where precision is emphasized. The 6 mg strength is preferred in scenarios requiring larger total systemic amounts, such as severe scabies or strongyloidiasis, where fewer tablets improve adherence and simplify administration. Both strengths remain fully interchangeable.
Pricing varies by manufacturer and region, but 3 mg tablets are often more widely available as generics, making them cost‑efficient. The 6 mg strength may carry a slight premium due to fewer manufacturers producing it. Branded Stromectol versions of both strengths are typically more expensive than generics.
The 3 mg strength is the most globally distributed form of oral ivermectin, produced by many generic manufacturers. The 6 mg strength is available in fewer markets but is increasingly common due to demand for simplified tablet counts. Both strengths deliver identical systemic efficacy.
| Parameter | 3 mg | 6 mg |
|---|---|---|
| Dosing flexibility | Maximum precision; fine‑tuned mg/kg construction | Fewer tablets; simplified administration |
| Clinical scenarios | Lower‑weight categories; precision‑focused regimens | Higher systemic totals; convenience‑focused regimens |
| Cost | Often cheaper; widely available as generics | Slightly higher; fewer manufacturers |
| Availability | Global distribution; many generic producers | Growing availability; fewer producers |
Ivermectin 3 mg (generic) and Stromectol 3 mg (brand‑name) contain the same active ingredient and provide identical systemic antiparasitic activity. The distinction lies in branding, excipients, regulatory positioning, and commercial factors rather than therapeutic performance. Stromectol is the originator brand and is often referenced in clinical literature, while generic ivermectin is produced by multiple manufacturers. More details on the branded formulation are available on Stromectol.
Stromectol represents the brand‑name reference product, manufactured under a single, standardized excipient profile. Generic ivermectin 3 mg tablets are produced by numerous manufacturers worldwide. Despite differences in branding and inactive ingredients, therapeutic efficacy, mechanism of action, and systemic distribution remain identical. Regulatory agencies consider generics fully interchangeable with Stromectol.
Both Stromectol and generic ivermectin exhibit equivalent oral bioavailability, influenced by ivermectin’s lipophilicity, CYP3A4 metabolism, and increased absorption with high‑fat meals. Minor excipient variations do not meaningfully affect systemic exposure. Clinical studies and pharmacokinetic comparisons consistently show no significant difference between brand and generic formulations.
The most notable distinction is price. Stromectol carries a brand‑name premium and is often significantly more expensive than generic ivermectin 3 mg. Generics benefit from competitive manufacturing and broader global distribution, making them the cost‑efficient option in most markets. Pricing details for the branded product are available at Stromectol price.
| Parameter | Generic Ivermectin 3 mg | Stromectol 3 mg |
|---|---|---|
| Brand status | Multiple manufacturers; generic formulation | Originator brand; single manufacturer |
| Bioavailability | Equivalent systemic exposure | Equivalent systemic exposure |
| Cost | Lower; widely available | Higher; brand‑name premium |
| Availability | Global distribution; many generics | Limited to specific markets |
The Ivermectin 3 mg tablet is the most widely distributed and commercially accessible strength of oral ivermectin. Its pricing varies across regions, manufacturers, and distribution channels, but it consistently remains the lowest‑cost ivermectin strength due to broad generic production. A more detailed overview of market pricing is available on Ivermectin price.
The 3 mg tablet is produced by numerous generic manufacturers, resulting in competitive pricing and wide availability. Because it is the historical reference strength used in clinical guidelines, it is stocked more consistently than higher strengths. Prices vary depending on pharmacy markup, supply chain stability, and regional regulations, but 3 mg tablets typically represent the most affordable option in the ivermectin category.
While Ivermectin 6 mg offers convenience by reducing tablet count, it is generally more expensive per tablet and sometimes per milligram. Fewer manufacturers produce the 6 mg strength, which can lead to higher retail prices and limited availability in certain markets. In contrast, the 3 mg strength benefits from large‑scale generic production, making it the cost‑efficient choice for constructing informational weight‑based regimens.
Several commercial variables affect the final retail price of ivermectin 3 mg: manufacturing origin, regulatory environment, import restrictions, pharmacy pricing policies, and fluctuations in global demand. Branded versions such as Stromectol typically carry a premium, while generics remain the dominant and most economical option.
| Parameter | Value |
|---|---|
| Typical 3 mg price | Lowest cost; broad generic availability |
| Comparison with 6 mg | 3 mg cheaper; 6 mg carries a convenience premium |
| Cost factors | Manufacturer, region, regulations, supply chain stability |